Introduction
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in surgical techniques and systemic therapies, recurrence and metastasis continue to limit patient survival. Identifying the molecular drivers of aggressive tumor behavior is critical for developing new prognostic markers and therapeutic strategies. The MEX3 family of RNA-binding proteins, particularly MEX3A, has recently emerged as a potential oncogenic factor in various malignancies. This study investigates the expression and functional role of MEX3A in NSCLC.
Methods
This research utilized a dual approach, integrating clinical data with experimental molecular biology.
Clinical Analysis: Immunohistochemistry (IHC) was performed on tumor specimens from 87 NSCLC patients (collected between 2014 and 2019) to evaluate MEX3A expression and its correlation with clinicopathological features such as tumor size and TNM stage.
Cellular Assays: The study employed a panel of NSCLC cell lines (including A549 and H1299) and a normal bronchial epithelial control (HBE). MEX3A levels were manipulated using siRNA-mediated knockdown and plasmid-driven overexpression.
Functional and Pathway Analysis: Proliferation was assessed via MTT and colony formation assays, while migration and invasion were measured using Transwell assays. Western blotting was used to monitor the expression of downstream signaling proteins, including P-MEK, P-ERK, and cell cycle regulators. To confirm the mechanism, the MEK inhibitor U0126 was used in rescue experiments to determine if blocking the pathway could neutralize MEX3A's effects.
Results
Clinical Significance of MEX3A
MEX3A was found to be significantly overexpressed in NSCLC tissues compared to normal tissues, with primary localization in the cell nucleus. High MEX3A expression levels were strongly associated with unfavorable clinical parameters, including poor tumor differentiation ($P=0.044$), larger tumor size ($P=0.020$), positive lymph node status ($P=0.001$), and advanced p-TNM stage ($P=0.009$).
Promotion of Malignant Phenotypes
In vitro experiments demonstrated that MEX3A is a potent driver of cancer progression. Overexpression of MEX3A significantly enhanced the proliferative, migratory, and invasive capabilities of NSCLC cells. Conversely, silencing MEX3A with siRNA inhibited colony formation ($P=0.0002$ in A549 cells) and reduced the metastatic potential of the cells.
Activation of the MEK/ERK Signaling Pathway
The study identified the MEK/ERK pathway as the primary mediator of MEX3A’s oncogenic effects. MEX3A overexpression led to increased phosphorylation (activation) of MEK and ERK, along with the upregulation of downstream targets involved in the cell cycle (CyclinA2, CDK4, CDK6) and structural remodeling (RhoA, MMP2). Crucially, treatment with the MEK inhibitor U0126 effectively reversed the MEX3A-induced increases in cell proliferation and invasion, confirming that MEX3A operates as an upstream activator of this classic signaling cascade.
Discussion and Conclusion
The findings establish MEX3A as a key regulator of NSCLC progression. By modulating the MEK/ERK pathway, MEX3A influences a broad suite of proteins involved in both growth and metastasis. While the precise molecular bridge between MEX3A and MEK/ERK activation requires further elucidation—potentially through transcriptomic analysis of MEX3A's RNA-binding targets—the strong correlation between MEX3A expression and poor clinical outcomes suggests its utility as a prognostic biomarker. Furthermore, targeting the MEX3A-MEK/ERK axis may offer a novel therapeutic avenue for patients with aggressive NSCLC, potentially helping to overcome resistance to standard radiotherapy and chemotherapy.
Summary updated